KCFBiopharma – Advanced Tissue-Engineered Wound Care Products

KCFBiopharma is a biotechnology company dedicated to developing innovative cell based therapies for chronic wound care.

When added to healthcare providers’ lineup of possible treatments for these conditions, KCFB’s products will help successfully treat more chronic venous wounds, improve patient comfort, and reduce healthcare costs associated with treating chronic wounds.

KCFB’s treatments have already been used in a large patient population in the EU with positive results. Now, we’re ready to begin the process of pursuing registration of this treatment in order to make it available to the medical community in EU and in the US.

Chronic venous wounds, such as leg and foot ulcers, are considered by many in the healthcare industry to be the silent epidemic of the 21st century.

Much of that cost can be attributed to the inefficiency and ineffectiveness of existing treatment options, and a failure by leading wound care companies to innovate and improve, more effective treatment options. 

The medical community needs new, innovative, effective methods for treating the “silent epidemic” of chronic wounds. In recent years, regenerative medicine — the science of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function — has emerged as a promising alternative to traditional, minimally effective treatment methods.

Regenerative medicine is the new frontier of treatment, and KCFBiopharma is leading the way. 

KCFBiopharma uses state-of-the-art cell based therapy approaches to develop advanced tissue-engineered wound care products.

KCFB’s products use a combination of  human cells  to restore the health of tissues and organs affected by leg ulcers and other chronic venous wounds. Our products allow the safe use of human tissue in the form of allogeneic cells acting as biocarriers of proteins contained in the cell nuclei. These act as natural antibiotics and antinflammatories to restore the natural microenvironment of the wounds necessary to achieve healing. KCFB has developed two products, each using a different type of cells to promote healing:

KCFB’s treatments have been shown to be effective for treating chronic venous leg ulcers that are unresponsive or recurrent following other conventional standard of care products. Because each of KCFB’s products features only one type of human cell, healthcare professionals will be able to more accurately determine when our products are indicated for a patient’s condition, and more accurately predict what the outcome of the treatment will be. 

In short: by adding KC Plus and FB Plus to their roster of wound care options, healthcare providers can:

Successfully treat more chronic venous wounds

Improve patient comfort and recovery times

Reduce costs associated with treating chronic wounds 

KCFB’s products use a combination of  human cells  to restore the health of tissues and organs affected by leg ulcers and other chronic venous wounds. Our products allow the safe use of  human tissue in the form of allogeneic cells acting as biocarriers of proteins contained in the cell nuclei. These act as natural antibiotics and antinflammatories to restore the natural microenvironment of the wounds necessary to achieve healing. KCFB has developed two products, each using a different type of cells to promote healing:

The results have shown excellent efficacy outcome with a good tolerability and safety profile. 80% of patients treated with KC Plus product saw a reduction of at least 50% within 5 weeks, while 71% of patients treated with FB Plus product saw similar results. Both KC Plus and FB Plus highly and significantly improve Wound Bed Score, a rating system used to evaluate the quality of wound care.

KCFBiopharma is in the final stages of preparation for two patents to protect the innovations behind our KC Plus and FB Plus products.

With data from a large patient population, KCFB is ready to advance its development program in EU, where it is already underway, and in the United States as well.

For more information about the future of KCFB and how you can be involved, please request access to the Business Plan tab of this funding profile.

KCFBiopharma is helmed by a team of seasoned medical professionals with decades of experience spanning wound care, pharmaceutical research and development, biochemistry and molecular biology, and business development.

Professor Jones is a member of the Board Directors for a number of pharmaceutical and biotechnology companies. He is a visiting professor at King’s College, London, and holds honorary degrees and gold medals from 6 universities. Professor Jones was for 12 years a member of the UK Government Regulatory Agency (the Medicines Commission), an advisor to the Cabinet Office on the Human Genome Project, a member of the Prime Minister’s task force on the competitiveness of the pharmaceutical industry, and Chair of the UK Government Advisory Group on Genetics Research.

Massimo Costa is a seasoned healthcare industry executive with significant entrepreneurial experience in the healthcare field. Previous to KCBF, he founded Tissuelab Spa, an international therapeutics company that processes muscle-skeletal human tissue, and AT Grade Srl, which used its own proprietary technology to manufacture ATMPs based on autologous and allogeneic human cells for the regeneration of dermis, epidermis and cartilage. Mr. Costa is a Biotech Group member of the National Association of Pharmaceutical Industries in Rome, and a member of the Aspen Institute, an International association of entrepreneurs, bankers and politicians. In addition to his position as CEO of KCFB, Mr. Costa is also a founding shareholder and CEO of Blast Research, which is in the process of obtaining market authorization for an advanced therapies medicinal product (ATMP) to treat scars in plastic and reconstructive surgery, and a Board Member at Athena Srl, the leading Italian company for devices for the treatment of peripheral blood and adipose tissue in orthopaedic and plastic surgery.

Dr. Noseda brings more than 25 years of experience in the pharmaceutical industry to the KCFB team. He has been responsible for the clinical development of pharmaceutical and diagnostic products. Between 1998 and 2012, he served as Head of the Scientific Office of R&D at Sigma-tau Spa in Pomezia. From 2012 to 2014, he served as Director of Scientific Office and Alliances for Sigma Tau, where he worked directly with the Corporate R&D Director and contributed to the growth of Sigma Tau’s R&D Portfolio with an active role in finding new opportunities and establishing operations in coordinating research and development activities for key projects.He is currently CEO of Sigma-tau Research Switzerland and CMO of the Sigma-tau Rare Disease organization.

Professor Brambilla is currently the Head of the Wound Care Unit at the Instituti Clinici Zucchi in Monza Italy, and Professor of Plastic Surgery at the University of Milan. He earned his degree in Medicine and Surgery from the University of Milan in 1979, and has more than three decades of experience as a practicing physician and surgeon.

Professor Passi is an Instructor of Biochemistry and Applied Biochemistry at the University of Pavia School of Medicine. He is a member of the Italian Biochemistry Society, the Italian Connective Tissue Society, the International Society of Matrix Biology, the American Society for Matrix Biology and the American Society of Biochemistry and Molecular Biology.

Mr. Owen currently is a partner/director at KCFBiopharma, he studied business at Napa College and Fresno State University. Over the last 25 years he has been officer, principle and trader, developing disruptive technology and real estate whilst managing and investing in the start-up of multiple companies.

DISCLAIMER: This is not a public solicitation to sell.